Aktis Oncology, Inc. Common stock (AKTS) — Cash Flow Reinvestment Rate

Latest as of December 2024: 12.90x

Aktis Oncology, Inc. Common stock (AKTS) has a Cash Flow Reinvestment Rate of 12.90x as of December 2024, reinvesting $190.40 Million (capex $2.86 Million plus investments $-187.54 Million) from operating cash flow of $14.76 Million. Explore cash flow conversion of Aktis Oncology, Inc. Common stock to assess how effectively this company generates cash.

Reinvestment Rate

12.90x
(Capex + Investments) / Operating CF

Total Reinvested

$190.40 Million
Capex + Investments

Operating Cash Flow

$14.76 Million
USD

Capital Expenditures

$2.86 Million
USD

Aktis Oncology, Inc. Common stock Cash Flow Reinvestment Rate (2024–2024)

Historical reinvestment intensity for Aktis Oncology, Inc. Common stock across 1 annual periods. Explore AKTS long-term investment intensity to see how much of total assets are deployed in long-term investments.

Annual Cash Flow Reinvestment Rate for Aktis Oncology, Inc. Common stock (2024–2024)

Year-by-year capital reinvestment analysis for Aktis Oncology, Inc. Common stock. For live market cap and broader valuation context, see market cap of Aktis Oncology, Inc. Common stock.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2024 12.90x $190.40 Million $14.76 Million $2.86 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow